What exactly did the FDA approve and why does it matter for NVO stock?

The FDA approved the first oral version of Wegovy for weight loss, a notable shift from injections to a pill. This can lower barriers to starting therapy and improve adherence, potentially broadening demand. That prospect drove NVO stock higher today as investors priced in faster adoption and a larger market.

Why did NVO stock trade on such heavy volume today?

The approval is a major catalyst that can impact revenue trajectory, so funds and traders repriced shares quickly. Volume rose to roughly 67 million versus a ~12.6 million average as price pushed above key bands, signaling strong interest and short-term momentum after the positive regulatory news.

What price levels are most important now for NVO stock?

Near term, the 50-day average around $49.82 is key support. The Keltner upper band near $52.14 and the $52-$53 zone form initial resistance. With ATR near 1.68, swings can be wider than usual. A firm close above resistance would strengthen the odds of continued upside.

How do valuation and fundamentals look after the pill approval?

Shares trade near 14.1 times earnings and 4.31 times sales, with sizable margins and strong returns. Dividend yield is about 2.56%. Balance sheet liquidity is tighter, so execution on supply and coverage is important. If adoption scales as hoped, fundamentals can stay supportive, but risks remain.

Global Market Insights

NVO Stock Today, December 23: FDA OKs First Oral Wegovy; Volume Soars

ByHuzaifa Zahoor December 24, 2025December 24, 2025

Shares of NVO surged after the FDA cleared the first oral Wegovy, marking a milestone for oral GLP-1 weight loss therapy. NVO stock traded near $51.91, up about 7% on roughly 67 million shares, far above the ~12.6 million average. The move signals rising confidence that pills can expand access and adherence versus injections. Below, we break down what approval means for Novo Nordisk shares, today’s price action, valuation, and the near-term setup for U.S. investors.